Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Ya-Ting | - |
dc.contributor.author | Coombs, Geoffrey | - |
dc.contributor.author | Ling, Thomas | - |
dc.contributor.author | Balaji, V. | - |
dc.contributor.author | Rodrigues, Camilla | - |
dc.contributor.author | Mikamo, Hiroshige | - |
dc.contributor.author | Kim, Min-Ja | - |
dc.contributor.author | Rajasekaram, Datin Ganeswrie | - |
dc.contributor.author | Mendoza, Myrna | - |
dc.contributor.author | Tan, Thean Yen | - |
dc.contributor.author | Kiratisin, Pattarachai | - |
dc.contributor.author | Ni, Yuxing | - |
dc.contributor.author | Barry, Weinman | - |
dc.contributor.author | Xu, Yingchun | - |
dc.contributor.author | Chen, Yen-Hsu | - |
dc.contributor.author | Hsueh, Po-Ren | - |
dc.date.accessioned | 2021-09-03T05:47:23Z | - |
dc.date.available | 2021-09-03T05:47:23Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 0924-8579 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83366 | - |
dc.description.abstract | This study was conducted to investigate the epidemiology and antimicrobial susceptibility patterns of Gram-negative bacilli (GNB) isolated from intra-abdominal infections (IAIs) in the Asia-Pacific region (APR) from 2010-2013. A total of 17 350 isolates were collected from 54 centres in 13 countries in the APR. The three most commonly isolated GNB were Escherichia coli (46.1%), Klebsiella pneumoniae (19.3%) and Pseudomonas aeruginosa (9.8%). Overall, the rates of extended-spectrum beta-lactamase (ESBL)-producing E. coli and K. pneumoniae were 38.2% and 24.3%, respectively, and they were highest in China (66.6% and 38.7%, respectively), Thailand (49.8% and 36.5%, respectively) and Vietnam (47.9% and 30.4%, respectively). During 2010-2013, the rates of ESBL-producing E. coli and K. pneumoniae isolates causing community-associated (CA) IAIs (collected <48 h after admission) were 26.0% and 13.5%, respectively, and those causing hospital-associated (HA) IAIs were 48.0% and 30.6%, respectively. Amikacin, ertapenem and imipenem were the most effective agents against ESBL-producing isolates. Piperacillin/tazobactam displayed good in vitro activity (91.4%) against CA ESBL-producing E. coli. For other commonly isolated Enterobacteriaceae, fluoroquinolones, cefepime and carbapenems exhibited better in vitro activities than third-generation cephalosporins. Amikacin possessed high in vitro activity against all GNB isolates (>80%) causing IAIs, except for Acinetobacter calcoaceticus-baumannii (ACB) complex (30.9% for HA-IAI isolates). All of the antimicrobial agents tested exhibited <45% in vitro activity against ACB complex. Antimicrobial resistance is a persistent threat in the APR and continuous monitoring of evolutionary trends in the susceptibility patterns of GNB causing IAIs in this region is mandatory. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | ANTIMICROBIAL RESISTANCE TRENDS | - |
dc.subject | AMPC BETA-LACTAMASES | - |
dc.subject | PIPERACILLIN-TAZOBACTAM | - |
dc.subject | ESCHERICHIA-COLI | - |
dc.subject | ENTEROBACTERIACEAE | - |
dc.subject | SMART | - |
dc.subject | BACTEREMIA | - |
dc.subject | CARBAPENEMASES | - |
dc.subject | CEFEPIME | - |
dc.subject | PROGRAM | - |
dc.title | Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Min-Ja | - |
dc.identifier.doi | 10.1016/j.ijantimicag.2017.01.030 | - |
dc.identifier.scopusid | 2-s2.0-85018976801 | - |
dc.identifier.wosid | 000402468100010 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v.49, no.6, pp.734 - 739 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | - |
dc.citation.volume | 49 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 734 | - |
dc.citation.endPage | 739 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ANTIMICROBIAL RESISTANCE TRENDS | - |
dc.subject.keywordPlus | AMPC BETA-LACTAMASES | - |
dc.subject.keywordPlus | PIPERACILLIN-TAZOBACTAM | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | ENTEROBACTERIACEAE | - |
dc.subject.keywordPlus | SMART | - |
dc.subject.keywordPlus | BACTEREMIA | - |
dc.subject.keywordPlus | CARBAPENEMASES | - |
dc.subject.keywordPlus | CEFEPIME | - |
dc.subject.keywordPlus | PROGRAM | - |
dc.subject.keywordAuthor | Antimicrobial susceptibility | - |
dc.subject.keywordAuthor | Epidemiology | - |
dc.subject.keywordAuthor | Gram-negative bacilli | - |
dc.subject.keywordAuthor | Intra-abdominal infection | - |
dc.subject.keywordAuthor | Extended-spectrum beta-lactamase | - |
dc.subject.keywordAuthor | Asia-Pacific region | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.